Invisible Epigenetic Shadow: DNA Methylation Field Effect Detected Around Kidney Tumors

Kidney tumors may cast a molecular shadow far beyond their visible borders. A new study from researchers at Maastricht University Medical Center, published in Epigenetics Communications, reports that histologically normal kidney tissue surrounding renal cell carcinoma (RCC) carries DNA methylation alterations resembling those found in the tumors themselves. The findings provide fresh support for the existence of a DNA methylation field effect in RCC and, perhaps more consequentially, reveal that the standard practice of using tumor-adjacent tissue as a control in biomarker studies may systematically underestimate how well diagnostic markers actually perform.

The concept of a field effect dates back to the 1940s and early 1950s, when Slaughter and colleagues observed that tissue appearing benign next to oral cancers was often histologically abnormal, and that surgically resected patients frequently developed new tumors at the same site. They coined the terms field effect and field cancerization to describe a broad swath of predisposed tissue from which malignancies can arise. Since then, the phenomenon has been documented in gastrointestinal, lung, head and neck, breast, skin, and urological cancers, though research has shifted from microscopic evaluation toward molecular signatures. Contiguous epithelial tumors such as those of the head and neck, skin, gastrointestinal tract, and bladder tend to fit a monoclonal expansion model, whereas glandular tumors of the prostate and breast are often, though not always, linked to polyclonal expansion. More recently, computational modeling and spatial omics approaches have begun to map these altered fields with unprecedented resolution.

DNA methylation, a chemical modification of cytosine bases that can silence gene expression without changing the underlying sequence, has emerged as one of the most tractable molecular readouts of field cancerization. Prior work in RCC offered suggestive evidence: a comparison of renal tumors, matched normal renal tissues, and kidneys from healthy volunteers found that the average number of methylated CpG islands was highest in tumors, but matched normal tissue showed more methylation than tissue from healthy individuals. Notably, the degree of methylation in matched normal samples correlated with a higher histological grade of the corresponding tumors. If a methylation field effect exists in RCC, it could potentially flag patients at risk of local recurrence or metastasis, which occurs in up to 20 percent of patients curatively treated with partial or radical nephrectomy, and might even serve as a molecular check on surgical resection margins.

The Maastricht team, led by Kim Lommen and Kim M. Smits, focused on five candidate genes previously implicated in RCC diagnosis or field effects: ANGPTL6, ANKRD34B, CAIX, NHLH2, and ZIC1. ANGPTL6 encodes angiopoietin-like protein 6, linked to angiogenesis and tissue remodeling, while CAIX encodes carbonic anhydrase IX, a well-established RCC-associated protein regulated by the hypoxia sensor HIF-1α. NHLH2 has been associated with metastatic progression in RCC, and ANKRD34B and ZIC1 have been flagged in age-related methylation studies of normal kidney tissue. The researchers quantified promoter methylation using quantitative methylation-specific PCR (qMSP) with hydrolysis probes, normalizing results against ALU repeat elements and expressing methylation as the percentage of methylated reference (%PMR), a standard approach validated in prior MethyLight methodology studies.

The study drew on two patient cohorts. The first, a hospital-based series collected between 1995 and 2008 from archives in Leuven and Maastricht, comprised 86 RCC tumor samples, 28 matched adjacent normal (AN) tissue samples from the same patients, and 47 normal kidney (NK) samples obtained from non-cancerous kidneys, including autopsy material. The second was a prospective pathological series of 11 patients who underwent nephrectomy in 2019 and 2020, from whom five formalin-fixed, paraffin-embedded blocks were sampled per patient: the tumor core (C0), the tumor-to-normal transition zone (C1), and three additional samples spaced one centimeter apart moving away from the tumor (C2 through C4). An experienced pathologist blindly confirmed the histological status of every sample using hematoxylin and eosin staining.

The results were striking. Methylation was present in 26 to 59 percent of RCC samples depending on the gene, and in 0 to 54 percent of matched adjacent normal samples, but in only 2 percent of normal kidney samples across all five markers. For ANKRD34B, no adjacent normal sample showed methylation at all, while 26 percent of tumors did. Concordance between tumor and adjacent tissue varied by gene: every AN sample methylated for NHLH2 came from a patient whose tumor was also methylated, whereas for ZIC1 only 42.8 percent of methylated adjacent samples corresponded to methylated tumors. In the spatial series, mean %PMR across all genes declined gradually from 12.4 percent at the tumor core to 5.8 percent at the sample farthest from the tumor, and methylation outside the tumor core appeared across all stages, grades, tumor diameters, and histological subtypes, suggesting the effect was not driven by aggressive disease alone.

The most practically important finding emerged when the team recalculated diagnostic biomarker performance using different control tissues. When ROC curve analysis compared RCC cases against adjacent normal tissue, estimated sensitivities ranged from 11.6 percent for CAIX to 55.8 percent for ANGPTL6. When the same tumors were compared against normal kidney tissue from non-cancerous patients, sensitivities rose to between 25.6 and 59.3 percent. The largest gap appeared for ZIC1, a 30.2 percentage point difference. Specificities were similar in both analyses except for ANGPTL6, which jumped from 57.1 to 97.9 percent when normal kidney tissue replaced adjacent tissue as the control. The methylation present in adjacent normal tissue effectively shifts the cutoff for test positivity, masking the marker’s true discriminatory power.

The implications for the biomarker field are considerable. In a previous systematic review, the same group found that two-thirds of studies evaluating diagnostic DNA methylation biomarkers in kidney tissue used adjacent normal tissue as controls, and only one-third used tissue from non-cancerous patients. Given the new data, many published estimates of biomarker sensitivity may have been artificially depressed, not because the markers were weak but because the comparison group was molecularly contaminated. The authors advocate that diagnostic biomarker studies use normal tissue from non-cancerous patients as controls rather than tumor-adjacent tissue, a methodological correction that could reshape how candidate markers are triaged for further development.

The study’s authors are careful to frame the spatial findings as exploratory. The pathological series included only 11 patients, too few to analyze histological subtypes separately, and the RCC and normal kidney cohorts differed in age, a confounder given that age-dependent methylation of ANKRD34B and ZIC1 in normal kidney tissue has been reported. Although all extra-tumoral samples were histologically normal, the presence of scattered tumor cells cannot be entirely excluded, so methylation detected in the C2 through C4 samples cannot be attributed to a true epigenetic field effect with certainty. No follow-up data on recurrence or metastasis were yet available, leaving open whether the observed methylation patterns carry prognostic or predictive value.

Future work, the team argues, should scale up sample sizes, apply genome-wide methylation profiling to the same spatial sampling design, and integrate computational and spatial omics approaches to determine whether the observed patterns extend across the genome and reflect biologically functional changes. If validated, field methylation markers could eventually be monitored through liquid biopsies of blood or urine during post-nephrectomy surveillance, offering a non-invasive window onto residual molecular risk. For now, the study delivers a dual message: kidney tumors may leave an epigenetic fingerprint in the tissue around them, and the way researchers choose their control tissue can make the difference between a biomarker that looks mediocre and one that reveals its true potential.

Subject of Research: A DNA methylation field effect in tissue surrounding renal cell carcinoma and its impact on diagnostic biomarker evaluation

Article Title: Exploring a DNA methylation field effect in renal cell carcinoma and its implications for biomarker research

Article References: Exploring a DNA methylation field effect in renal cell carcinoma and its implications for biomarker research. (n.d.). https://doi.org/10.1186/s43682-026-00052-8

Image Credits: AI Generated

DOI: 10.1186/s43682-026-00052-8

Keywords: DNA methylation, renal cell carcinoma, field effect, field cancerization, epigenetics, biomarker, qMSP, kidney cancer, ANGPTL6, CAIX, ZIC1, control tissue